Posted by Clinical Lab Products | Aug 28, 2009 | Cancer, Miscellaneous |
Abbott announced that it has entered into an agreement with Pfizer Inc to develop a molecular diagnostic test intended to screen non-small cell lung cancer (NSCLC) tumors for the presence of gene rearrangements.
Read MorePosted by Clinical Lab Products | Aug 28, 2009 | Cancer, Miscellaneous |
Gen-Probe Incorporated (NASDAQ: GPRO) announced that the Company has begun a clinical trial intended to secure U.S. regulatory approval of its PROGENSA PCA3 assay, a new molecular test that may help determine the need for a repeat prostate biopsy.
Read MorePosted by Clinical Lab Products | Aug 24, 2009 | Cancer, Miscellaneous |
AMDL Inc announces the inauguration of AMDL Diagnostics Inc (ADI), a new wholly-owned subsidiary that will focus on the research, development, manufacture and international sales of Onko-SureAMDL’s proprietary, regulatory approved in vitro diagnostic (IVD) cancer test.
Read MorePosted by Clinical Lab Products | Aug 3, 2009 | Cancer, Miscellaneous |
DxS Ltd announces it is working closely with AstraZeneca to make available a companion diagnostic for use with IRESSA (gefitinib), AstraZenecas treatment for non small cell lung cancer (NSCLC).
Read MorePosted by Clinical Lab Products | Jul 15, 2009 | Cancer, Molecular Diagnostics |
Abbott and GlaxoSmithKline (GSK) will develop an automated molecular diagnostic test intended to screen non-small cell lung cancer (NSCLC) tumors for expression of the MAGE-A3 antigen.
Read More